Danish insulin maker Novo Nordisk plans to file for regulatory approval for its new anti-obesity drug in Mexico, in a bid to tackle one of the root causes of diabetes in a key market.

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo’s ...

COPENHAGEN (Reuters) - Novo Nordisk (NOVOb.CO) has launched its type 2 diabetes treatment Ryzodeg in Mexico, a combination drug that could reap the company billions in revenues in years to come.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Earlier this year, Novo Nordisk said it would target Mexico as its next market for an obesity-fighting formula of liraglutide, sold for diabetes as Victoza. Now, the company has picked Mexico for ...

Danish pharma company Novo Nordisk has not had the best of times with its diabetes pipeline of late, but chalked up a success with the first launch of its Ryzodeg combination insulin product in Mexico ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.

Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased competition for its ...